Emma Andersson
Overview
Explore the profile of Emma Andersson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
565
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xia Y, Caputo M, Andersson E, Asiedu B, Zhang J, Hou W, et al.
Cell Mol Gastroenterol Hepatol
. 2025 Mar;
:101485.
PMID: 40024534
Background & Aims: Hepatocellular carcinoma (HCC) is a rapidly growing malignancy with high mortality. Recently, metabolic dysfunction-associated steatohepatitis (MASH) has emerged as a major HCC catalyst; however, signals driving transition...
2.
Cansby E, Caputo M, Andersson E, Saghaleyni R, Henricsson M, Xia Y, et al.
J Lipid Res
. 2024 Oct;
65(11):100669.
PMID: 39395791
Metabolic dysfunction-associated steatotic liver disease has emerged as a leading global cause of chronic liver disease. Our recent translational investigations have shown that the STE20-type kinases comprising the GCKIII subfamily-MST3,...
3.
Andersson E, Ost M, Dalla K, Zetterberg H, Blennow K, Nellgard B
Neurocrit Care
. 2024 May;
41(3):813-827.
PMID: 38769253
Background: This study investigated trajectory profiles and the association of concentrations of the biomarkers neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in ventricular cerebrospinal fluid (CSF) with clinical...
4.
Caputo M, Andersson E, Xia Y, Hou W, Cansby E, Erikson M, et al.
Int J Mol Sci
. 2024 Feb;
25(4).
PMID: 38397122
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its advanced subtype, metabolic dysfunction-associated steatohepatitis (MASH), have emerged as the most common chronic liver disease worldwide, yet there is no targeted pharmacotherapy...
5.
Xia Y, Andersson E, Caputo M, Cansby E, Sedda F, Font-Girones F, et al.
Mol Med
. 2023 Oct;
29(1):138.
PMID: 37864157
Objective: Non-alcoholic fatty liver disease (NAFLD), the primary hepatic consequence of obesity, is affecting about 25% of the global adult population. The aim of this study was to examine the...
6.
Caputo M, Xia Y, Anand S, Cansby E, Andersson E, Marschall H, et al.
FASEB J
. 2023 Jul;
37(8):e23105.
PMID: 37490000
Hepatocellular carcinoma (HCC) is one of the most fatal and fastest growing malignancies. Recently, nonalcoholic steatohepatitis (NASH), characterized by liver steatosis, inflammation, cell injury (hepatocyte ballooning), and different stages of...
7.
Gonzalez-Ortiz F, Dulewicz M, Ashton N, Kac P, Zetterberg H, Andersson E, et al.
JAMA Netw Open
. 2023 Jul;
6(7):e2321554.
PMID: 37399012
Importance: Blood-based measurements of total tau (T-tau) are commonly used to examine neuronal injury in patients with traumatic brain injury (TBI), but current assays do not differentiate between brain-derived tau...
8.
Xia Y, Andersson E, Anand S, Cansby E, Caputo M, Kumari S, et al.
Hepatol Commun
. 2023 Mar;
7(4).
PMID: 36930872
Background: NAFLD has become the leading cause of chronic liver disease worldwide afflicting about one quarter of the adult population. NASH is a severe subtype of NAFLD, which in addition...
9.
Mattila K, Makela S, Kytola S, Andersson E, Vihinen P, Ramadan S, et al.
Acta Oncol
. 2022 Oct;
61(10):1263-1267.
PMID: 36307938
Background: Detectable circulating tumor DNA (ctDNA) has been associated with worse prognosis in melanoma patients. Material And Methods: We studied plasma ctDNA as a prognostic biomarker in 19 patients with...
10.
Anand S, Caputo M, Xia Y, Andersson E, Cansby E, Kumari S, et al.
J Lipid Res
. 2022 Jun;
63(7):100238.
PMID: 35679904
The primary hepatic consequence of obesity is non-alcoholic fatty liver disease (NAFLD), affecting about 25% of the global adult population. Non-alcoholic steatohepatitis (NASH) is a severe form of NAFLD characterized...